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Improving understanding of the genetic basis of human non-alcoholic fatty liver  disease 
(NAFLD) has the potential to facilitate risk stratification of affected patients, permit 
personalized treatment, and inform development of new therapeutic strategies. Animal 
models have been widely used to interrogate the pathophysiology of, and genetic predis-
position to, NAFLD. Nevertheless, considerable interspecies differences in intermediary 
metabolism potentially limit the extent to which results can be extrapolated to humans. 
For example, human genome-wide association studies have identified polymorphisms in 
PNPLA3 and TM6SF2 as the two most prevalent determinants of susceptibility to NAFLD 
and its inflammatory component (NASH), but animal models of these mutations have 
had only variable success in recapitulating this link. In this review, we critically appraise 
selected murine monogenic models of NAFLD, NASH, and hepatocellular carcinoma 
(HCC) with a focus on how closely they mirror human disease.
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iNTRODUCTiON
Non-alcoholic fatty liver disease (NAFLD) is a pandemic disorder associated with premature 
morbidity and mortality. Its etiology is multifactorial, with both genetic predisposition and envi-
ronmental factors playing important parts (1). Animal models have been central to recent major 
translational research efforts, serving as discovery tools to identify new candidate pathogenic 
mechanisms, as a means of testing hypotheses arising from human studies, and as pre-clinical mod-
els in which to assess potential therapeutic strategies (2). There are multiple different experimental 
perturbations known to trigger NAFLD in animal models, which have been used to generate all 
components of the NAFLD spectrum (3–10). Such perturbations include genetic manipulation 
(e.g., ob/ob mouse), pro-steatotic or pro-inflammatory diets [e.g., methionine–choline deficient 
(MCD) diet], and toxic insults (e.g., streptozotocin injection). Combinations of these may be 
used to reflect the multifactorial nature of the human disease (e.g., ob/ob mice fed a MCD diet); 
however, a detailed discussion of rodent diets is beyond the scope of this review.
While animal models do potentially give key insights into the disease process that cannot be 
obtained through any other means, it is necessary to temper appreciation of this utility with under-
standing of the limitations of each of the models used.
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We, now, briefly review the current understanding of the 
genetic architecture of human NAFLD, and the major approaches 
adopted to modeling it in animals, while critically appraising the 
utility of these models.
OveRview OF NON-ALCOHOLiC FATTY 
LiveR DiSeASe PATHOGeNeSiS
Human NAFLD is defined by the presence of macrovesicular 
steatosis in more than 5% of hepatocytes in individuals with 
a history of less than 20  g/day ethanol intake (11). The dif-
ferentiation of macrovesicular from microvesicular steatosis is 
a qualitative histological assessment, and the two may coexist 
in more advanced disease (12). NAFLD exists as a pathological 
spectrum ranging from non-alcoholic fatty liver (NAFL, also 
known as “simple” steatosis), which denotes hepatic steatosis 
in the absence of steatohepatitis, through to non-alcoholic 
steatohepatitis (NASH), in which there is histological evi-
dence of inflammatory infiltrates, hepatocyte ballooning 
(featuring Mallory-Denk bodies), and commonly fibrosis of 
varying severity. Cirrhosis can develop at the most severe end 
of the spectrum, conferring increased risk of hepatocellular 
carcinoma (HCC), portal hypertension, and liver failure (13). 
Longitudinal studies have shown 10–20% of patients with each 
stage of disease to progress to the following stage in, while 
there is also an element of reversibility, particularly in NAFL 
and NASH (14, 15).
A “two-hit hypothesis” has been suggested to account for the 
pathogenesis of advanced NAFLD, whereby the first “hit” drives 
development of steatosis and the second triggers inflammation 
and its sequelae, critically including fibrosis (16).
In principle, hepatic steatosis may result from pre-hepatic 
derangements, intra-hepatic derangements, or both, as illus-
trated in simplified form in Figure 1. A comprehensive review 
of pathways leading to hepatic steatosis is beyond the scope 
of this article and is provided elsewhere (17–19). In brief, 
pre-hepatic pathogenic factors encompass increased substrate 
flux to the liver (e.g., non-esterified free fatty acids (NEFA), 
monosaccharides, or amino acids) and dysregulation of hor-
mones that act directly on hepatocyte metabolism (e.g., insu-
lin, glucagon and related peptides, and adipokines). Increased 
“preload” in the form of NEFA delivery generally results from 
failure of adipose tissue adequately to buffer positive energy 
balance. This may be a consequence of hyperphagic obesity, in 
which even normal adipose buffering capacity is overwhelmed, 
or lipodystrophy, in which adipose energy buffering capacity 
is pathologically constrained. In some situations, a mixture 
of these is at play, as in generalized lipodystrophy, where the 
harmful results of absent adipose tissue are potentiated by 
concomitant lack of leptin.
Many pre-hepatic hormonal factors also influence propen-
sity to NAFLD by acting on adipocytes to modulate lipolysis 
and/or through direct actions on hepatocytes (e.g., insulin, 
glucagon, glucagon-like peptides). There has been a particular 
focus on the ability of high levels of insulin, secondary to 
peripheral insulin resistance, to drive hepatic de novo lipo-
genesis. Another emerging influence on liver metabolism is 
the gut microbiome, which may affect gut hormone release 
and also signal directly through flux of bacterial metabolites 
such as acetate (20, 21).
Hepatocyte-autonomous (intra-hepatic) defects may also 
lead to triglyceride accumulation. Such defects may broadly be 
classified into: those increasing de novo synthesis of triglyceride; 
those perturbing lipid droplet dynamics, triglyceride mobiliza-
tion and lipoprotein assembly or secretion; and those impairing 
catabolism of fatty acids by beta-oxidation. Although reduced 
ability to catabolize fatty acids via beta-oxidation (e.g., due to 
Mendelian disorders in key catabolic enzymes, or mitochondrial 
dysfunction) does result in hepatic steatosis, however, this is 
usually microvesicular in appearance and has a distinct clini-
cal profile that often includes hypoglycemia, liver failure, and 
encephalopathy (22). These disorders will, thus, not be discussed 
further here.
Development of NASH is multifactorial; a comprehensive 
review of the inflammatory and fibrotic sequelae of hepatic lipid 
accumulation can be found elsewhere (23–26). Key elements of 
pathogenesis include oxidative stress (from lipid peroxidation and 
mitochondrial dysfunction) and activation of pro-inflammatory 
pathways (e.g., NF-κB) in hepatocytes, but other cellular path-
ways, including the endoplasmic reticulum stress response, have 
also been implicated (27). Coactivation of Kupffer cells, sinusoi-
dal endothelium, and hepatic stellate cells gives rise to cytokines 
that augment inflammation [e.g., tumor necrosis factor alpha 
(TNFα), interleukin-1/-6] and drive fibrosis [e.g., transforming 
growth factor beta (TGFβ)] (19, 28, 29). These processes are also 
exacerbated by pre-hepatic factors, such as adipose inflamma-
tion/lipotoxicity, gut bacterial translocation, and endogenous 
alcohol production.
HUMAN GeNeTiCS OF NAFLD
In the vast majority of patients, NAFLD is a multifactorial con-
dition rooted in obesity and insulin resistance, based on strong 
clinical association and natural history studies in humans. 
Pandemic, idiopathic NAFLD is often referred to as “primary” 
NAFLD (30). Genetics can play a role in each stage of the patho-
physiology of NAFLD, as illustrated both by rare monogenic 
conditions that feature severe NAFLD, and by the association 
of much more frequent single nucleotide polymorphisms 
(SNPs) with “common” NAFLD (31–33). The proliferation of 
recent human genetic findings puts their detailed treatment 
beyond the scope of this discussion; however, we select a series 
of mechanistically informative sentinel examples to appraise 
against rodent models.
“PRe-HePATiC” NAFLD
Monogenic Hyperphagic Obesity
Flux of substrates, such as free fatty acids, amino acids, and 
lactate, provide the building blocks for hepatocyte triglyceride 
accumulation as well as the energy required for activation 
of anabolic pathways (see Figure  1). Excess flux can thus be a 
potent driver for NAFLD. Most attention has been paid to flux 
of free fatty acids, the product either of lipolysis of triglyceride 
FiGURe 1 | Factors implicated in hepatic steatosis. Pre-hepatic factors lead to increased substrate flux to the liver by both increased load (e.g., raised fatty 
acid delivery) and altered composition (e.g., increased fructose). Hyperphagia causes provision of excess macronutrients, which contributes to overload of white 
adipose tissue (via obesity). Lipodystrophy causes functional or anatomical failure of adipose, with the resulting spill over of substrates passing to the liver. Insulin 
resistance contributes to hormonal changes (e.g., raised insulin, low adiponectin) that alter intra-hepatic metabolism of lipids. Intestinal dysbiosis influences both 
substrate delivery to the liver and generation of gut-derived hormones (e.g., elevated GLP-1). Key: hormones are in blue, examples of genes involved in monogenic 
disorders are in green, and examples of genes with pro-steatotic common polymorphisms are in red.
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in adipose tissue or lipolysis of triglyceride in triglyceride-rich 
lipoproteins such as chylomicron remnants. Key determinants of 
free fatty acid flux to the liver are thus the dietary intake of fat 
and the efficiency of fatty acid trapping and storage in adipose 
tissue. Correspondingly, in states of hyperphagia or adipose tissue 
insufficiency, free fatty acid flux may be pathologically increased. 
Of note, “adipose tissue insufficiency” may arise from overload 
of adipose tissue that is normal or increased in amount, or may 
arise from frank anatomical deficiency of adipose tissue, or 
lipodystrophy.
Several human examples of monogenic hyperphagia exist. The 
first to be discovered was congenital leptin deficiency (34), with 
loss-of-function mutations in the leptin receptor gene discovered 
later (35). Leptin is an adipose-derived peptide adipokine that 
acts on the hypothalamus to signal replete energy stores and sup-
press appetite (36). It is expressed and secreted by white adipose 
tissue (WAT) in direct proportion to WAT volume, and serum 
levels fall commensurately with depletion of adipose stores dur-
ing starvation. Primary leptin deficiency produces severe, hyper-
phagic obesity from a young age; however, liver fat accumulation 
has only rarely been commented on in published studies. In one 
study, severe NAFLD was identified in an obese leptin-deficient 
child that resolved quickly on introduction of recombinant leptin 
therapy (37). The long-term hepatic outcome of untreated human 
leptin deficiency or leptin receptor mutation is not known; how-
ever, leptin receptor polymorphisms have been associated with 
NASH and insulin resistance in patients with NAFLD (38, 39).
Several other forms of human monogenic obesity are now 
known. In contrast to genetic leptin or leptin receptor loss-of-
function, which are extremely rare, heterozygous mutations in 
the melanocortin-4-receptor (MC4R) are the most common 
monogenic cause of obesity, accounting for around 6% of severe, 
early-onset obesity (40). There are no published reports of the 
impact of heterozygous MC4R mutations on hepatic steatosis in 
monogenic obesity, while polymorphisms in MC4R have been 
associated with alanine aminotransferase and BMI (41), but not 
with hepatic fat content in population-wide studies (42). Several 
other genes have been implicated in human monogenic obesity; 
however, in aggregate, these affect only a very small number of 
patients, and there is little information on the liver phenotype. 
Moreover, some of the gene products involved, such as prohor-
mone convertase 1 and pro-opiomelanocortin have pleiotropic 
roles, not just in appetite control but also in the action of key 
peripheral hormones (peptide and steroid hormones respec-
tively) which have independent effects on liver fat accumulation, 
so shall not be considered here.
The sparse attention paid in published human reports to the 
natural history of NAFLD in human monogenic obesity is likely 
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to be attributable to the rarity of the diseases, to the fact that most 
patients identified are children in whom clinically overt liver 
NAFLD has not yet had time to develop and to that fact that, in 
leptin deficiency, curative therapy with recombinant human lep-
tin is the standard of care. This means that the long-term natural 
history of NAFLD in leptin deficiency will be extremely difficult 
to document in future, although determining the long-term liver 
outcome of MC4R loss-of-function should be both tractable and 
informative.
Monogenic Lipodystrophy
In the face of severe hyperphagia, the ability even of “normal” 
adipose tissue to buffer chronic positive energy balance by 
trapping and sequestering lipid is finite and is eventually 
overwhelmed, leaving the liver exposed to excess free fatty acid 
flux. However, some rare humans have a congenital deficiency 
of adipose tissue, which we shall consider only in its most 
severe, generalized form. In this situation, there is effectively 
absolute adipose failure, and complete lack of energy buffering 
is compounded by secondary lack of leptin and consequent 
hyperphagia, as the hypothalamus erroneously interprets very 
low or absent leptin as an indication of starvation. Around 95% 
of cases in humans congenital generalized lipodystrophy (CGL) 
are accounted for by biallelic mutations in either AGPAT2, 
encoding an enzyme involved in triglyceride synthesis, or in 
BSCL2, encoding an endoplasmic reticulum protein involved 
in lipid droplet regulation and adipocyte differentiation (43, 
44). A clinical hallmark of CGL is very severe NAFLD, with 
early development of inflammation, fibrosis, and HCC. Indeed, 
clinical experience and published case series suggest that com-
plications of advanced liver disease are among the major sources 
of mortality in CGL (45, 46). Observations in CGL and other 
acquired and genetic lipodystrophies establish unequivocally 
that primary disorders of adipose tissue are sufficient to cause 
the full spectrum of NAFLD in humans (47). This does not prove 
that adipose dysfunction is the primary mechanism at play in 
pandemic NAFLD; however, current population-wide data do 
not rule this out.
endocrine Drivers
Many hormones exert a major influence on lipid accumulation 
within hepatocytes, although in each case this is only possible 
in the context of adequate energy charge and substrate flux to 
the liver, so these cannot easily be teased apart. Hormones of 
proven importance in altering liver lipid accumulation include 
insulin, glucagon, and the incretin gut peptides (e.g., GLP-1). 
In humans, insulin has attracted particular attention as several 
lines of evidence suggest that insulin, acting through the insulin 
receptor, stimulates de novo lipogenesis sufficiently to make a 
major contribution to liver fat accumulation in NAFLD (48–50). 
Some negative evidence in support of this model comes from 
the observation that humans with loss-of-function mutations in 
the insulin receptor itself, although showing very severe insulin 
resistance, are protected from dyslipidemia and liver fat accumu-
lation (51). Preliminary evidence suggests that this also holds for 
patients with lipodystrophy and loss-of-function mutations in 
PIK3R1, a component of phosphatidylinositol-3-kinase involved 
in insulin signaling (52).
HePATOCYTe-AUTONOMOUS NAFLD
Lipid Trafficking Abnormalities
Some genetic abnormalities can influence development of 
steatosis by hepatocyte-autonomous mechanisms. One of these 
mechanisms is impaired assembly and export of lipoproteins 
from hepatocytes, leading to intracellular accumulation of tri-
glycerides. The best examples of this are heterozygous truncating 
mutations in APOB [encoding apolipoprotein B (ApoB)], causing 
hypobetalipoproteinaemia and biallelic mutations in MTTP 
(encoding microsomal triglyceride transfer protein), which cause 
abetalipoproteinaemia (53). These two conditions have a similar 
phenotype including NASH, low serum triglycerides, low LDL 
cholesterol, and neuropathy. Patients often develop progressive 
NASH with fibrosis even in the absence of diabetes, obesity, or 
other oxidative stresses (53, 54).
Further evidence in support of altered lipoprotein assembly 
and secretion as a significant player in NAFLD comes from 
GWAS of the commoner form of the disease. These have impli-
cated a SNP in TM6SF2 (encoding transmembrane 6 superfamily 
member 2), which is needed for secretion of very-low density 
lipoproteins (VLDL), in NAFLD. The risk allele is found in 
around 1% patients with NAFLD (55) and correlates positively 
with serum aminotransferase levels (33), hepatic steatosis (31), 
NASH activity, and fibrosis (but not HCC) (56). Importantly, 
patients with this SNP have lower circulating LDL cholesterol, 
lower triglycerides, and reduced incidence of atherosclerotic 
disease, providing an example of dissociation of NAFLD from 
dyslipidemia and cardiovascular disease (57). Data relating to 
the association with insulin resistance and type 2 diabetes are 
currently inconclusive (58).
Population-wide human genetics has also implicated funda-
mental abnormalities in lipid droplets in NAFLD: for example, 
the p.Ile148Met SNP in PNPLA3, whose product is patatin-like 
phospholipase domain-containing 3, is associated with all stages 
of NAFLD, from simple steatosis, NASH, fibrosis, and develop-
ment of HCC (59, 60). PNPLA3 (also known as adiponutrin) 
is a membrane-bound enzyme expressed at the surface of lipid 
droplets and on the smooth endoplasmic reticulum (61) and 
plays a role in lipid droplet dynamics. There has been conflict-
ing evidence on whether this polymorphism is associated with 
insulin resistance, however.
inflammation/Fibrosis
Inflammation and fibrosis are the hallmarks of complicated 
NAFLD, and a genetic basis for the susceptibility to these 
complications is often mooted as the “second hit” needed to 
drive progression from simple steatosis to inflammatory and 
fibrotic sequelae. Unsurprisingly, no single gene examples of 
a primary inflammatory or fibrotic disorders leading to end 
stage NAFLD have been reported (62, 63); however, the GWAS 
approach has identified common genetic variants associated with 
progression of fibrosis (e.g., near the gene for platelet-derived 
TABLe 1 | examples of murine genetic models relevant to “pre-hepatic” NAFLD.
Model Obesity insulin resistance Hyper-lipidemia Liver steatosis NASH Fibrosis HCC
Hyperphagic models
Ob/ob (64) Y Y Y Y Y Y (mild) ?
Db/db (64) Y Y Y Y Y Y (mild) ?
Mc4r−/− on HFD (65) Y Y Y Y Y Y Y
Lipodystrophic models
Agpat2−/− (66) N Y N Y ? ? ?
Bscl2−/− N Y N Y ? ? ?
A-ZIP/F-1 (67) N Y Y Y ? ? ?
Adipose-specific Insr knockout (68) N Y Y Y Y Y Y
Liver insulin action
Liver-specific Pten knockout (69) N N N Y Y (mild) Y Y
Features are based on ad libitum standard chow diet, unless otherwise stated. ob/ob is a leptin-deficient mouse; db/db is a leptin-resistant mouse; MC4R−/− mouse is a mouse 
with hypothalamic hyperphagia; Agpat2−/− and Bscl2−/− are lipodystrophic mice with functional and anatomical failure of white adipose; A-ZIP/F-1 is a lipodystrophic mouse due to 
specific failure of white adipose differentiation; adipose-specific insulin-receptor (Insr) knockout causes lipodystrophy; and liver-specific phosphatase and tensin homolog (PTEN) 
knockout disrupts hepatocyte insulin signaling.
HCC, hepatocellular carcinoma; HFD, high-fat diet; NASH, non-alcoholic steatohepatitis; Y, yes; N, no; ?, insufficient data.
TABLe 2 | examples of murine genetic models relevant to “intrahepatic” NAFLD.
Model Obesity insulin resistance Hyper-lipidemia Liver steatosis NASH Fibrosis HCC
impaired lipoprotein synthesis/secretion
Apob−/− (70) N N Y Y Y Y N
Fatty liver Shionogi (FLS) (71) N Y N Y Y Y Y
FLS-ob/ob mouse (72) Y Y Y Y Y Y Y
Tm6sf2 knockdown (32) N Y Y Y N N N
Abnormal lipid droplet dynamics
Hepatic-specific PNPLA3 I148M expression (73) N Y N Y N N N
Features are based on ad libitum standard chow diet. Apob−/− mouse is unable to secrete VLDL from hepatocytes; fatter liver Shionogi mice are thought to also have impaired VLDL 
secretion; FLS-ob/ob are FLS mice crossed with leptin-deficient mice; Transmembrane 6 superfamily 2 (Tm6sf2) knockdown mice have reduced triglyceride secretion; hepatic-
specific expression of the human I148M allele of patatin-like phospholipase domain-containing 3 (PNPLA3) causes altered lipid droplet composition and storage.
NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; Y, yes; N, no.
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growth factor alpha) or with the development of lobular inflam-
mation (e.g., near genes encoding interleukin-6, or collagen type 
XIII alpha 1).
RODeNT GeNeTiC MODeLS OF NAFLD
The ideal “one stop” animal model of NAFLD would recapitulate 
the full progression from simple steatosis through NASH to 
fibrosis, cirrhosis, and HCC. Ideally, the disease process would 
progress rapidly (in contrast to the human condition) to maxi-
mize experimental tractability of the model. However, a valid 
alternative would be to have a series of different models for 
different stages of the disease sequence, which may be primar-
ily metabolic, inflammatory, or fibrotic. It has been suggested 
that the primary goal of rodent models should be to mimic the 
pathology of NAFLD, including the underlying histopathology 
(3). On this narrow basis, it has been argued that rodents do not 
accurately model human NAFLD because of differences in bal-
looning degeneration and distribution of inflammatory infiltrate 
in NASH (4).
Many animal models have been described in which different 
degrees of NAFLD are seen, and we shall consider selected models 
only as examples, classifying them into two groups according to 
the broad pathogenic mechanism at play: (1) models of “extrahe-
patic” NAFLD (Table 1) and (2) models of “intrahepatic” NAFLD 
(Table 2).
MURiNe “PRe-HePATiC” NAFLD
Hyperphagic Models
The severely obese ob/ob mouse strain arose spontaneously in 
1949, and was eventually discovered in 1994 to harbor a loss-of-
function mutation in the gene encoding leptin, thereby ushering 
in the modern era of investigation of the neuroscience of appetite 
control. Given an ad  libitum diet, ob/ob mice develop obesity, 
insulin resistance, hyperglycemia, and hepatic steatosis (74), and 
they have been become a highly popular model for many aspects 
of obesity and related disorders, either being studied in isolation, 
or crossed with other strains of interest in order to determine 
the effect of severe hyperphagia on mice with different genetic 
perturbations. The severe obesity of ob/ob mice is attributable 
to hypothalamic hyperphagia; however, several studies have 
provided evidence for additional peripheral effects of leptin to 
modulate insulin sensitivity and metabolism directly in tissues, 
such as muscle and liver. Whether such peripheral effects are also 
seen in humans remains to be established beyond doubt (75–77).
6Mann et al. Monogenic Rodent Genetic Models of NAFLD
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The ob/ob mouse rapidly develops NAFL and at 20 weeks old 
early features of NASH are present (77, 78). NASH may been 
accelerated by a second “hit” of inflammatory/oxidative stress, 
using, for example, intraperitoneal injection of lipopolysaccha-
ride (LPS) (79), dietary stressors such as a MCD diet (80), or 
crossing with another NASH-prone strain, such as the fatty liver 
Shionogi (FLS) mice, which are discussed later (81). Notably, 
however, leptin is required for normal immune function, and 
its deficiency dampens down both innate and acquired immune 
responses in humans (82, 83), though it seems to play a pro-
inflammatory and pro-fibrogenic role in mice (78). This may 
explain why the inflammatory components of NAFLD appear 
relatively indolent in ob/ob mice than in more common NAFLD. 
On a related note, it has also be shown that the ob/ob mouse 
is relatively resistant to fibrosis (78, 80), partly due to reduced 
release of TNFα, which is necessary for activation of TGFβ, a key 
pro-fibrogenic molecule (84–86).
Collectively, these findings caution that, while the ob/ob mouse 
is a valuable model of primary hyperphagia-driven NAFLD, loss 
of specific actions of leptin on peripheral metabolism, coupled 
to some degree of immunosuppression, means that it is likely 
to deviate from pandemic NAFLD in key respects, especially 
related to the inflammatory and fibrotic end of the disease 
spectrum. Similar arguments may apply to leptin-resistant db/
db mice, which harbor a splice site mutation abolishing expres-
sion of the long form of the leptin receptor; however, db/db mice 
are reported to exhibit more severe NAFLD than ob/ob mice 
(64, 80). In practice, a secondary stressor is also usually applied 
when using db/db mice to study NAFLD, with the MCD diet 
being widely used (87).
Mice in which Mc4r is genetically ablated have also been widely 
studied. Their primary defect lies within hypothalamic appetite 
control pathways, as the melanocortin 4 receptor responds to the 
neuropeptide α-MSH, which is generated in response to leptin 
action. Mc4r-null mice feature hyperphagic obesity without 
pathologically suppressed leptin levels, suggesting that they 
have the potential to model the extended spectrum of NAFLD 
more faithfully than ob/ob mice. In keeping with this, it has been 
reported that Mc4r-knockout mice, when exposed to a high-fat 
diet, develop not only steatosis but also exuberant NASH with 
established fibrosis after 20 weeks, progressing to HCC in all mice 
studied by 1 year (65).
Lipodystrophic Models
Many different murine genetic models of lipodystrophy have 
been described. Where direct comparison is possible between 
mice and humans, it has been found that the common forms of 
CGL are well modeled in mice, while the situation for human 
genetic forms of partial lipodystrophy is more complex, and will 
not be discussed further here (45).
Both Agpat2- and Bscl2-knockout mice have been 
described (88, 89). Agpat2 encodes 1-acylglycerol-3-phosphate 
O-acyltransferase 2 and is needed for synthesis of triacylglycerols 
and glycerolphospholipids in white adipose. Many Agpat2−/− mice 
die in the first few weeks of life; however, the survivors accurately 
recapitulate the human condition of lipodystrophy with severe 
insulin resistance (66). Hepatic steatosis has also been reported 
to be a major feature of the mice before 16 weeks old, with liver 
weights twice normal, and modest inflammatory changes seen 
in addition to pronounced steatosis. More detailed time course 
studies of the liver disease in this model have not been reported, 
however.
Bscl2 encodes seipin, which is needed for both differentiation 
of white adipocytes and normal lipid droplet regulation, and 
deficiency has been suggested to shift the balance toward release 
of free fatty acids from adipocytes (89). Bscl2−/− mice display a 
lipodystrophic phenotype with near complete absence of WAT. 
Massive hepatic steatosis is a feature of all three Bscl2−/− models 
described. As in Agpat2 null mice, however, detailed natural 
history studies of liver pathology have not been reported: at 
12 weeks, there is no evidence of NASH but there are no reported 
data beyond this age (90).
Although not directly modeling human disease, some other 
murine models have provided powerful evidence for the impor-
tance of adipose tissue in protection from NAFLD. One impactful 
model is the A-ZIP/F-1 (or “AZIP”) mouse, which is an adipose-
deficient mouse generated by transgenic overexpression of an arti-
ficially engineered dominant negative protein that interferes with 
critical adipogenic transcription factors. This causes deficiency 
of white adipose, severe insulin resistance, and hepatic steatosis, 
although it was said not to feature inflammation at the relatively 
young age studied (67). It is not known whether these mice 
develop NAFLD-related fibrosis, in part because of the reduced 
survival of the mice, which are severely diabetic. A much more 
recent model featured knockout of the insulin receptor selectively 
in adipose tissue, knockout being mediated by cre recombinase 
driven by the adipose-specific adiponectin promoter (68). These 
mice developed severe lipodystrophy and fatty liver disease very 
early, and by 12 weeks old, livers demonstrated not only steatosis 
but also increased ROS, lipid peroxidation, ballooning degenera-
tion of hepatocytes, and elevated serum transaminase levels. By 
1 year old the liver accounted for 25% of body weight and showed 
highly dysplastic liver nodules in addition to worsened inflam-
mation and fibrosis. High fat feeding worsened the liver injury.
Liver insulin Action
Although it is impossible to mimic a primary increase in insulin 
without inducing complex and potentially confounding changes 
to systemic metabolism, liver-specific knockout of the insulin 
receptor does afford the opportunity to test the proposition 
that liver insulin action is necessary for the development of 
hepatic steatosis. Indeed, in 2008, it was reported that ablation 
of the insulin receptor in mouse liver, although inducing severe 
systemic insulin resistance, did not increase liver triglyceride or 
liver weight (91).
Conversely, liver-specific knockout of the phosphatase and 
tensin homolog (PTEN), which is a phosphatidylinositol-3,4,5-
triphosphate (PIP3) phosphatase that serves to antagonize 
insulin’s metabolic actions, produces macrovesicular stea-
tosis, NASH (including Mallory-Denk bodies), fibrosis, and 
HCC (69). Similarly, other modes of genetic activation of 
phosphatidylinositol-3-kinase pathway signaling also produce 
steatosis that progresses to HCC, but without such marked 
steatohepatitis (92, 93).
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HePATOCYTe-AUTONOMOUS 
MURiNe NAFLD
impaired Lipoprotein Synthesis/Secretion
Assembly and secretion of VLDL represents a major route for the 
final disposition of intrahepatocyte triglyceride. Apolipoprotein 
B (ApoB) is a core component of VLDL particles, and genetic 
partial deficiency in humans causes familial hypobetalipopro-
teinaemia. Homozygous loss-of-function mutations of ApoB in 
mice cause embryonic lethality due to exencephalus. However, 
several different lines of mice heterozygous for mutated ApoB 
have been described, and these accurately recapitulate the 
hepatic steatosis, low serum triglycerides, and low HDL choles-
terol of the human condition, although little fibrosis has been 
reported in the absence of additional pro-inflammatory stimuli 
(70, 94). Nevertheless, an important caveat is that natural history 
of liver inflammation and fibrosis has not been reported beyond 
12 weeks of age. Similar to humans with hypobetalipoproteinae-
mia, mice with reduced ApoB function do not show marked 
insulin resistance, which differentiates them from most patients 
with NAFLD.
The FLS mouse is a further NAFLD model, which arose 
spontaneously as a result of inbreeding. FLS mice are non-obese 
and only mildly insulin resistant, but show marked accumulation 
of macrovesicular triglyceride with mononuclear inflammatory 
infiltrate and fibrosis, which eventually results in development 
of HCC by 13–16 months even without additional carcinogenic 
stimuli (95, 96). The precise underlying genetic defect is not yet 
known; however, a defect in microsomal triglyceride transfer 
protein (MTTP) (97) has been suggested. Precisely, why this 
model is so susceptible to HCC is not known. Crossing of FLS 
mice with ob/ob mice results in a model with the full metabolic 
syndrome and progressive fibrosis (81, 98); this model most 
closely recapitulates the whole human spectrum of NAFLD in a 
practical, experimental timeframe.
As discussed, human GWAS have shown a SNP in TM6SF2 
to be associated with NAFLD (99). Reminiscent of hypobetali-
poproteinaemia, however, carriers of the risk-conferring T-allele 
seem relatively protected from atherosclerotic disease despite 
increased lipid fat content. TM6SF2 is a membrane-bound 
protein located on the endoplasmic reticulum involved in the 
secretion of VLDL from hepatocytes (100). Germline knockout 
of Tm6sf− has not yet been described in mice; however, adeno-
associated virus-mediated knockdown selectively in mouse liver 
resulted in increased hepatic triglyceride content and reduced 
VLDL secretion (32). Moreover transgenic hepatocyte-specific 
expression of human wild-type TM6SF2 in mice caused an 
increase in serum LDL cholesterol and lower HDL cholesterol 
(101); however, the full spectrum of NAFLD has not been dem-
onstrated in this model.
ABNORMAL LiPiD DROPLeT DYNAMiCS
The p.Ile148Met variant in human PNPLA3, found in around 
20% of the population, is associated with NAFLD progression 
(55). Therefore, efforts have been made to generate a rodent 
model that recapitulates this genetic predisposing factor and 
to  elucidate the role of PNPLA3 in NAFLD. PNPLA3 is 
expressed in many tissues in mice, including WAT and liver 
(102). Expression is suppressed upon fasting (103) and upregu-
lated following a carbohydrate load (104), which is believed to 
be mediated by steroid regulatory element-binding protein- 1c 
(SREBP-1c) and carbohydrate-response element-binding pro-
tein (ChREBP). PNPLA3 was initially thought to function as 
a lipase and be involved in the release of triglycerides from 
intracellular lipid droplets (105–107), so it was hypothesized 
that reduced activity would increase hepatocellular triglyceride 
content (108).
If reduced PNPLA3 activity was to accelerate NAFLD, Pnpla3 
knockout mice would be expected to have severely fatty livers; 
however, in fact, they have no evidence of NAFLD (109). Indeed, 
there is no discernible difference between Pnpla3−/− and wild-
type mice even when fed high-fat diet or crossed onto the Lepob/ob 
background. It should be noted, however, that mice show the 
highest Pnpla3 expression in WAT, unlike humans, in whom 
expression is highest in the liver.
In contrast to the knockout mice, mice with hepatic overex-
pression of human PNPLA3 p.Ile148Met show increased hepatic 
triglyceride content and fatty acid synthesis (73, 110). They 
develop steatosis only on a normal chow or sucrose diet, but not 
on a high-fat diet, which suggests that the mutant PNPLA3 acts 
upon de novo fatty acids, rather than re-absorbed circulating non-
esterified fatty acids (111). This is consistent with epidemiological 
data that suggests fructose-rich diets are more harmful than high-
fat diets (112).
The cumulative data from these mouse models suggest that 
PNPLA3 functions as a lysophosphatidic acid acyltransferase, 
and that the p.Ile148Met polymorphism increases this activity, 
stimulating development of hepatic steatosis (113, 114). This 
would have not been identified without the initially surprising 
finding in the knockout model. Although mice with hepatic 
expression of human PNPLA3 p.Ile148Met develop NAFLD, it is 
not known whether these mice develop HCC with age as reported 
studies extend to only 12 weeks, however.
CONCLUSiON
The spectrum of human NAFLD disease arises from complex 
environmental influences allied to genetic predisposition. 
Human monogenic diseases demonstrate unequivocally 
that adipose tissue failure and primary genetic defects in 
intrahepatocyte lipid handling can give rise to NAFLD and its 
sequelae. Genetic perturbation in rodents may be combined 
with a pro-inflammatory or pro-steatotic diet to accelerate liver 
injury and mimic the multifactorial nature of human NAFLD. 
In general, murine genetic models closely mimic monogenic 
forms of NAFLD, where mouse and human liver phenotypes 
have been described in sufficient detail to draw conclusions; 
however, many gaps exist in descriptions of the natural history 
of NAFLD associated with several of the monogenic diseases in 
mice or humans. Findings in both species indicate that there is 
more than one possible pathogenic route to NAFLD, meaning 
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that study of several different human conditions and their 
models will be important to tease out common mechanisms of 
liver damage. A critical advantage of mouse models over humans 
is that the tremendously powerful technologies available to 
perturb genes conditionally or in an organ-specific way permits 
isolation of only some parts of a highly interconnected system. 
So, while alignment of humans and their murine models could 
be further refined, murine models are a highly valuable tool in 
the study of NAFLD.
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